Pediatrics in Review
HOME HELP CONTACT US SUBSCRIPTIONS CME ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text (PDF)
Right arrow Rapid Responses: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Rapid Responses are posted
Right arrow Alert me if a correction is posted
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My File Cabinet
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hoffman-Rosenfeld, J.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Hoffman-Rosenfeld, J.

Rubella Vaccine

Jamie Hoffman-Rosenfeld MD1
1 Albert Einstein College of Medicine, Bronx, NY

Editors: Henry M. Adam, MD.

Rubella usually is a mild viral illness characterized by an erythematous maculopapular rash, slight fever, and lymphadenopathy. Although serious complications of rubella, such as encephalitis and thrombocytopenia, are rare in children, the devastating consequences of the congenital rubella syndrome continue to propel a multipronged strategy to eliminate rubella infection.

Rubella vaccine is a live virus vaccine, which in the United States is the RA27/3 rubella virus strain grown in human diploid cell culture. Although one dose of vaccine confers lifelong immunity in greater than 90% of vaccine recipients, two doses now are recommended in conjunction with the measles vaccine. Because congenital rubella is a potentially devastating consequence of primary vaccine failure, the second dose of vaccine serves as an additional safeguard against such failures.







HOME HELP CONTACT US SUBSCRIPTIONS CME ARCHIVE SEARCH TABLE OF CONTENTS
Pediatrics  Pediatrics in Review
Copyright © 1995 by the American Academy of Pediatrics.